Epithelial Innate Immune Response to Oral Bacteria

上皮细胞对口腔细菌的先天免疫反应

基本信息

  • 批准号:
    7458100
  • 负责人:
  • 金额:
    $ 33.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-08-01 至 2010-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: This application will analyze the molecular mechanisms utilized by host gingival epithelial cells (GECs) in response to commensal and pathogenic oral bacteria, and the cellular receptors and signaling pathways associated with innate immunity in the periodontium. GECs respond to bacteria in an interactive manner secreting chemokines and cytokines to alert various cell types and attract neutrophils. They also produce natural antimicrobial peptides of the beta-defensin family. The defensin antimicrobial peptides are part of the innate immune system, a complex set of responses that keeps microbial invaders in check and maintains the microbial ecology of the healthy periodontal pocket. Human beta-defensin-2 (hBD-2) expression is upregulated in GECs in response to both commensal and pathogenic bacteria. In addition, this peptide is widely expressed in normal oral mucosa, in contrast to normal epidermis, suggesting that the innate immune responses of normal oral epithelia are at a heightened state of readiness. This application will test the hypotheses that commensal and pathogenic oral bacteria stimulate different networks of genes in gingival epithelial cells (GECs), that commensals prime the state of innate immunity of GECs for increased responsiveness to the environment and to subsequent exposure to pathogens, and that p-defensins are a major influence in this heightened innate immune response. These hypotheses build on evidence that commensal and pathogenic bacteria utilize different signaling pathways for regulation of hBD-2 gene expression and that hBD-2 itself influences innate immune responses and acts as a positive autocrine regulator. Finally, new evidence suggests involvement of the proteinase-activated receptor (PAR) family in innate immune and inflammatory responses. These receptors signal the presence of danger in the environment and contribute to inflammation. A final Aim will examine the function of these receptors to signal in response to Porphyromonas gingivalis, a major periodontopathogen that has proteinases as part of its set of virulence factors. These questions and hypotheses will be examined with the goal to better understand the global responses of GECs to commensal vs. pathogenic bacteria emphasizing gene expression programs and receptors that are critical for innate immune responses. This work will lay the groundwork for identifying new therapeutic targets to prevent and treat periodontal diseases.
描述:这项应用将分析宿主牙龈上皮细胞(GECs)响应共生和致病口腔细菌的分子机制,以及与牙周组织天然免疫相关的细胞受体和信号通路。GEC以一种相互作用的方式对细菌作出反应,分泌趋化因子和细胞因子来警告不同类型的细胞并吸引中性粒细胞。它们还产生β-防御素家族的天然抗菌肽。防御素抗菌肽是先天免疫系统的一部分,先天免疫系统是一组复杂的反应,可以阻止微生物入侵,并维持健康牙周袋的微生物生态。人类β-防御素-2(HBD-2)在GEC中的表达上调,对共生细菌和病原菌都有反应。此外,该多肽在正常口腔粘膜中广泛表达,与正常口腔黏膜相比,这表明正常口腔黏膜上皮的天然免疫反应处于高度准备状态。这一应用将检验这样的假设,即共生和致病口腔细菌刺激牙龈上皮细胞(GECs)中不同的基因网络,共生细菌启动GECs的天然免疫状态以提高对环境和随后接触病原体的反应,以及p-防御素是这种增强的先天性免疫反应的主要影响因素。这些假说建立在证据的基础上,即共生菌和病原菌利用不同的信号通路来调节HBD-2基因的表达,并且HBD-2本身影响先天免疫反应并发挥正向自分泌调节作用。最后,新的证据表明,蛋白酶激活受体(PAR)家族参与了先天免疫和炎症反应。这些受体发出环境中存在危险的信号,并导致炎症。最终目标将检查这些受体的功能,以响应牙龈卟啉单胞菌的信号,这是一种主要的牙周病原体,其毒力因子中含有蛋白酶。研究这些问题和假设的目的是更好地了解GEC对共生细菌和致病细菌的全球反应,重点是基因表达程序和受体,这些程序和受体对先天性免疫反应至关重要。这项工作将为寻找预防和治疗牙周病的新的治疗靶点奠定基础。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
PAR1- and PAR2-induced innate immune markers are negatively regulated by PI3K/Akt signaling pathway in oral keratinocytes.
  • DOI:
    10.1186/1471-2172-11-53
  • 发表时间:
    2010-10-28
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Rohani MG;DiJulio DH;An JY;Hacker BM;Dale BA;Chung WO
  • 通讯作者:
    Chung WO
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Whasun Oh Chung其他文献

Whasun Oh Chung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Whasun Oh Chung', 18)}}的其他基金

Dynamics of HIV-infection, Oral Innate Immunity and The Development of Oral Diseases in Children
HIV感染动态、口腔先天免疫和儿童口腔疾病的发展
  • 批准号:
    10534585
  • 财政年份:
    2022
  • 资助金额:
    $ 33.76万
  • 项目类别:
Dynamics of HIV-infection, Oral Innate Immunity and The Development of Oral Diseases in Children
HIV感染动态、口腔先天免疫和儿童口腔疾病的发展
  • 批准号:
    10653227
  • 财政年份:
    2022
  • 资助金额:
    $ 33.76万
  • 项目类别:
Balancing expression of PRRs in epithelial innate immune responses to bacteria
平衡上皮对细菌先天免疫反应中 PRR 的表达
  • 批准号:
    8460434
  • 财政年份:
    2009
  • 资助金额:
    $ 33.76万
  • 项目类别:
Balancing expression of PRRs in epithelial innate immune responses to bacteria
平衡上皮对细菌先天免疫反应中 PRR 的表达
  • 批准号:
    8270367
  • 财政年份:
    2009
  • 资助金额:
    $ 33.76万
  • 项目类别:
Balancing expression of PRRs in epithelial innate immune responses to bacteria
平衡上皮对细菌先天免疫反应中 PRR 的表达
  • 批准号:
    8063062
  • 财政年份:
    2009
  • 资助金额:
    $ 33.76万
  • 项目类别:
Balancing expression of PRRs in epithelial innate immune responses to bacteria
平衡上皮对细菌先天免疫反应中 PRR 的表达
  • 批准号:
    7825367
  • 财政年份:
    2009
  • 资助金额:
    $ 33.76万
  • 项目类别:
Balancing expression of PRRs in epithelial innate immune responses to bacteria
平衡上皮对细菌先天免疫反应中 PRR 的表达
  • 批准号:
    7631989
  • 财政年份:
    2009
  • 资助金额:
    $ 33.76万
  • 项目类别:
Epithelial Innate Immune Response to Oral Bacteria
上皮细胞对口腔细菌的先天免疫反应
  • 批准号:
    7255493
  • 财政年份:
    2005
  • 资助金额:
    $ 33.76万
  • 项目类别:
Regulation of Human Beta-Defensins in Epithelia
上皮细胞中人类β防御素的调节
  • 批准号:
    6954202
  • 财政年份:
    2004
  • 资助金额:
    $ 33.76万
  • 项目类别:
Regulation of Human Beta-Defensins in Epithelia
上皮细胞中人类β防御素的调节
  • 批准号:
    7111856
  • 财政年份:
    2004
  • 资助金额:
    $ 33.76万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.76万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了